Authors: Galagudza, Michael M.; Blokhin, Ilia O.; Shmonin, Aleksey A.; Mischenko, Kirill A.

Source: Cardiovascular & Haematological Disorders - Drug Targets, Volume 8, Number 1, March 2008 , pp. 47-65(19)

Publisher: Bentham Science Publishers

Abstract:

Reduction of infarct size as well as alleviation of other ischemia- and reperfusion-associated injuries are the goals of primary importance in cardiology. One of the remedies is considered to be myocardial preconditioning (PreCon) referred usually to as an increased myocardial tolerance to prolonged ischemia following brief ischemic or non-ischemic challenge. In this review, PreCon stimuli tested to date are considered including a number of mildly noxious factors applied either locally to the myocardium or systemically. Recently, one more mode of heart protection against reperfusion injury termed postconditioning (PostCon) has been developed. On the basis of ample evidence published, along with our findings, a detailed comparative analysis of PreCon and PostCon is presented, with special emphasis on the cellular, molecular, and pharmacological aspects of the topic as well as clinical applications, both implemented and awaiting practical approval.

Keywords: Heart; ischemia-reperfusion injury; infarct size; cardioprotection; preconditioning; postconditioning

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152908783884966

Publication date: 2008-03-01

More about this publication?

• Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Galagudza, Michael M. ;  Blokhin, Ilia O. ;  Shmonin, Aleksey A. ;  Mischenko, Kirill A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers